Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

205.07
-1.1600-0.56%
Post-market: 206.000.9300+0.45%19:59 EDT
Volume:27.98M
Turnover:5.74B
Market Cap:362.44B
PE:86.89
High:207.78
Open:206.27
Low:203.06
Close:206.23
52wk High:244.81
52wk Low:164.39
Shares:1.77B
Float Shares:1.76B
Volume Ratio:4.72
T/O Rate:1.59%
Dividend:6.65
Dividend Rate:3.24%
EPS(TTM):2.36
EPS(LYR):2.36
ROE:6225.00%
ROA:9.81%
PB:-110.84
PE(LYR):86.89

Loading ...

AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 13

AbbVie’s Korean Rinvoq Study Wraps Up, Bolstering Real-World Data for Immunology Growth

TIPRANKS
·
Feb 13

West Pharma forecasts 2026 profit above estimates on strong demand for drug components

Reuters
·
Feb 12

Abbvie Sues U.S. Department of Health and Human Services Over Selection of Botox for Ira Medicare Drug Negotiations

THOMSON REUTERS
·
Feb 12

Abbvie sues US health agency over Botox

Reuters
·
Feb 12

Neurocrine Biosciences Q4 GAAP other income rises 38% to USD 28.5 million

Reuters
·
Feb 12

AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury: What Investors Should Watch

TIPRANKS
·
Feb 12

AbbVie’s Real-World Migraine Study Could Quietly Boost Ubrogepant’s Market Potential

TIPRANKS
·
Feb 11

Enanta Pharmaceuticals Q1 revenue beats estimates

Reuters
·
Feb 10

BNP Paribas Exane Adjusts Price Target on AbbVie to $213 From $203, Maintains Neutral Rating

MT Newswires Live
·
Feb 09

AbbVie Seeks Rinvoq Vitiligo Approval And Extends Immunology Growth Story

Simply Wall St.
·
Feb 08

AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 07

AbbVie (ABBV) Receives a Buy from Guggenheim

TIPRANKS
·
Feb 06

CORRECTED-CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5)

Reuters
·
Feb 06

Abbvie Inc. : Morgan Stanley Raises Target Price to $270.00 From $269.00

THOMSON REUTERS
·
Feb 05

AbbVie Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Feb 05

AbbVie Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Feb 05

Morgan Stanley Lifts Price Target on AbbVie to $270 From $269, Keeps Overweight Rating

MT Newswires Live
·
Feb 05

BUZZ-Street View: AbbVie's strong drug pipeline sets it up well for long‑term growth

Reuters
·
Feb 05

U.S. RESEARCH ROUNDUP-Alphabet, Corteva, Varonis Systems

Reuters
·
Feb 05